<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent evidence has shown that p53 overexpression in leukemic cells may be a consequence of p53 gene mutation or can occur via posttranslational modification mechanisms </plain></SENT>
<SENT sid="1" pm="."><plain>While mutant forms of p53 may stimulate cell proliferation and transformation, <z:mp ids='MP_0002169'>wild-type</z:mp> p53 may inhibit DNA synthesis and cause leukemic cells to enter <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Nine bone marrow biopsies of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with known p53 overexpression were analyzed for evidence of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of both leukemic blasts and of background hematopoietic cells </plain></SENT>
<SENT sid="3" pm="."><plain>This was quantified and compared with that seen in p53- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and in <z:mpath ids='MPATH_458'>normal</z:mpath> control marrows </plain></SENT>
<SENT sid="4" pm="."><plain>The rate of cell <z:hpo ids='HP_0011420'>death</z:hpo> due to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was measured by in situ end-labeling of fragmented DNA with the following results: mean values of apoptotic cells/mm2 of BM, p53+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (9 cases), 2.41 +/- 1.7; p53- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (10 cases), 0.16 +/- 0.1; control marrows (20 samples), 0.05 +/- 0.0 </plain></SENT>
<SENT sid="5" pm="."><plain>Our results showed a significant association (P &lt; 0.001) between p53 overexpression and <z:mp ids='MP_0006042'>increased apoptosis</z:mp> in <z:hpo ids='HP_0000001'>all</z:hpo> cases studied </plain></SENT>
<SENT sid="6" pm="."><plain>The difference was entirely caused by the high rate of cell <z:hpo ids='HP_0011420'>death</z:hpo> observed in the erythroid and myeloid precursor cells of these marrows </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that p53+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are a distinct group of marrow disorders characterized by a high rate of intramedullary cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>This may explain why patients with p53+ leukemic disorders show excessive marrow sensitivity to chemotherapy with prolonged marrow suppression associated with the presence of cytogenetically abnormal blasts that display great drug resistance </plain></SENT>
</text></document>